Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Oaknin

Showing results (11-20 of 173) with videos related to

Pageof 18
Sort By:
Therapeutic Advances in Medical Oncology|April 3, 2023
Advances in immunotherapy for cervical cancerJuan Francisco Grau-Bejar, Carmen Garcia-Duran, David Garcia-Illescas, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 6, 2023
Advances in immunotherapy in cervical cancerJuan-Francisco Grau, Lorena Farinas-Madrid, Carmen Garcia-Duran, et al.
Expert Opinion on Investigational Drugs|February 21, 2023
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?Ignace Vergote, Isabelle Ray-Coquard, Domenica Lorusso, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 23, 2012
SEOM guidelines for endometrial cancerAna Oaknin, Víctor Rodríguez-Freixinós, Isabela Díaz de Corcuera, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 23, 2012
SEOM guidelines for cervical cancerAna Oaknin, Isabela Díaz de Corcuera, Víctor Rodríguez-Freixinós, et al.
The Oncologist|October 3, 2019
Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10Yvette Drew, Rebecca S Kristeleit, Ana Oaknin, et al.
Frontiers in Oncology|March 14, 2022
The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 PathwaysMichael J Birrer, Keiichi Fujiwara, Ana Oaknin, et al.
Immunotherapy|April 10, 2026
The game changer in the cervical cancer therapeutic landscape: immunotherapyRamon Yarza, Lorena Fariñas-Madrid, Carmen García-Duran, et al.
Cancer Treatment Reviews|July 31, 2021
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectationsHélène Vanacker, Philipp Harter, Sana Intidhar Labidi-Galy, et al.
ESMO Open|December 14, 2020
First-line PARP inhibitors in ovarian cancer: summary of an <i>ESMO Open - Cancer Horizons</i> round-table discussionSusana Banerjee, Antonio Gonzalez-Martin, Philipp Harter, et al.
Pageof 18

Showing results (11-20 of 173) with videos related to

Sort By:
Pageof 18
Therapeutic Advances in Medical Oncology|April 3, 2023
Advances in immunotherapy for cervical cancerJuan Francisco Grau-Bejar, Carmen Garcia-Duran, David Garcia-Illescas, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 6, 2023
Advances in immunotherapy in cervical cancerJuan-Francisco Grau, Lorena Farinas-Madrid, Carmen Garcia-Duran, et al.
Expert Opinion on Investigational Drugs|February 21, 2023
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?Ignace Vergote, Isabelle Ray-Coquard, Domenica Lorusso, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 23, 2012
SEOM guidelines for endometrial cancerAna Oaknin, Víctor Rodríguez-Freixinós, Isabela Díaz de Corcuera, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 23, 2012
SEOM guidelines for cervical cancerAna Oaknin, Isabela Díaz de Corcuera, Víctor Rodríguez-Freixinós, et al.
The Oncologist|October 3, 2019
Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10Yvette Drew, Rebecca S Kristeleit, Ana Oaknin, et al.
Frontiers in Oncology|March 14, 2022
The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-β and PD-L1 PathwaysMichael J Birrer, Keiichi Fujiwara, Ana Oaknin, et al.
Immunotherapy|April 10, 2026
The game changer in the cervical cancer therapeutic landscape: immunotherapyRamon Yarza, Lorena Fariñas-Madrid, Carmen García-Duran, et al.
Cancer Treatment Reviews|July 31, 2021
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectationsHélène Vanacker, Philipp Harter, Sana Intidhar Labidi-Galy, et al.
ESMO Open|December 14, 2020
First-line PARP inhibitors in ovarian cancer: summary of an <i>ESMO Open - Cancer Horizons</i> round-table discussionSusana Banerjee, Antonio Gonzalez-Martin, Philipp Harter, et al.
Pageof 18